Market Research Logo

Global Sexual Dysfunction Drugs Market 2017-2021

Global Sexual Dysfunction Drugs Market 2017-2021

About Sexual Dysfunction Drugs

Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market. Erectile dysfunction (ED) is a highly prevalent sexual dysfunction seen in men. Globally, there has been an increase in the number of ED cases caused due to high blood pressure, obesity, neurological and nerve disorders, prostate cancer, and diabetes among others.

Technavio’s analysts forecast the global sexual dysfunction drugs market to grow at a CAGR of 2.79% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global sexual dysfunction drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Sexual Dysfunction Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Bayer
  • Eli Lilly
  • Pfizer
Other prominent vendors
  • Apricus Biosciences
  • Emotional Brain
  • GlaxoSmithKline
  • Ivix LLX
  • Leadiant Biosciences
  • Merck
  • NexMed
  • Palatin Technologies and PRA Health Sciences
  • S1 Biopharma
  • Takeda
  • Teva Pharmaceutical Industries
  • Trimel Biopharma SRL
  • Vietstar Biomedical Research
Market driver
  • Rising prevalence of sexual dysfunctions
  • For a full, detailed list, view our report
Market challenge
  • Technological advancements, a threat to drug therapy
  • For a full, detailed list, view our report
Market trend
  • Increased focus on generic drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Sexual Dysfunction Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global sexual dysfunction drugs market: AbbVie, Bayer, Eli Lilly, and Pfizer.

Other Prominent Vendors in the market are: Apricus Biosciences, Emotional Brain, GlaxoSmithKline, Ivix LLX, Leadiant Biosciences, Merck, NexMed, Palatin Technologies and PRA Health Sciences, S1 Biopharma, Takeda, Teva Pharmaceutical Industries, Trimel Biopharma SRL, and Vietstar Biomedical Research.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increased focus on generic drugs. The global sexual dysfunction drugs market is currently witnessing an increasing focus of vendors toward the launch of generic drugs in the market. The patent expiration of many ED drugs has led to the entry of generics in the market. The cost-effective nature and the abundant availability of these drugs have led to the increase in the adoption rate of these drugs among physicians and end-users, thus adding to the market revenue.”

According to the report, one of the major drivers for this market is Rising prevalence of sexual dysfunctions. The global sexual dysfunction drugs market is currently witnessing an increasing prevalence rate of sexual dysfunction disorders in men and women. As per the NIH, the incidence rate of ED is 25-30 cases per thousand people per year globally, and this rate is directly proportional to age. A similar pattern is observed with women's sexual dysfunctions.

Further, the report states that one of the major factors hindering the growth of this market is Technological advancements, a threat to drug therapy. Many vendors in the market are innovating in terms of product technology to make ED solutions such as penile implants more reliable and natural-looking. For instance, Titan from Coloplast is made from Bioflex and silicone and is designed to imitate the appearance and mechanism of a natural erection. This will prompt more individuals to undergo penile implant surgeries to treat ED as these solutions provide a near-natural feel of penial erection.

Companies Mentioned

AbbVie, Bayer, Eli Lilly, Pfizer, Apricus Biosciences, Emotional Brain, GlaxoSmithKline, Ivix LLX, Leadiant Biosciences, Merck, NexMed, Palatin Technologies and PRA Health Sciences, S1 Biopharma, Takeda, Teva Pharmaceutical Industries, Trimel Biopharma SRL, Vietstar Biomedical Research

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
  • Disease overview
    • Sexual dysfunction: Definition
      • Table Symptoms of sexual dysfunction in men and women
      • Table Types of sexual disorder
    • Causes of sexual dysfunction
      • Table Causes of sexual dysfunction
      • Table Regional prevalence rate of ED June 2016
  • Market landscape
    • Market overview
      • Table Global sexual dysfunction drugs market: Snapshot
    • Market size and forecast
      • Table Global sexual dysfunction drugs market 2016-2021 ($ millions)
      • Table Key drugs patent expiration in major countries
      • Table Opportunity analysis of global sexual dysfunction drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline
    • Table Pipeline snapshot based on number of molecules 2016
    • Table Pipeline snapshot based on types of sexual dysfunction 2016
    • Table Key clinical trials
  • Market segmentation by therapy
    • Table Global sexual dysfunction drugs market segmentation by therapy 2016
    • Oral therapy
      • Table Oral therapies used as per drug class
      • Table Global sexual dysfunction oral drugs market 2016-2021 ($ millions)
    • Intracavernosal therapy
      • Table Intracavernosal therapy used as per drug class
      • Table Global sexual dysfunction intracavernosal drugs market 2016-2021 ($ millions)
      • Table Some marketed intracavernosal drugs
    • Hormonal therapy
      • Table Hormonal therapy used as per drug class
      • Table Global sexual dysfunction hormonal drugs market 2016-2021 ($ millions)
    • Transurethral therapy
      • Table Transurethral therapy used as per drug class
      • Table Global sexual dysfunction transurethral drugs market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Global sexual dysfunction drugs market share by geography 2016 and 2021
    • Table Global sexual dysfunction drugs market revenue by geography 2016-2021
    • Table Global sexual dysfunction drugs market share by geography 2016-2021
    • Table Snapshot of Global sexual dysfunction drugs market by geography 2016 and 2021
    • Sexual dysfunction drugs market in Americas
      • Table Market scenario in Americas
      • Table Sexual dysfunction drugs market in Americas 2016-2021 ($ millions)
    • Sexual dysfunction drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Sexual dysfunction drugs market in EMEA 2016-2021 ($ millions)
    • Sexual dysfunction drugs market in APAC
      • Table Market scenario in APAC
      • Table Sexual dysfunction drugs market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Prevalence data of sexual dysfunction in women and men every year
      • Table Geriatric population analysis and estimates 2000 and 2030 (millions)
      • Table Mean number of prostate cancer diagnoses by five-year age band 2008-2010
      • Table Prevalence of ED in stroke patients 2008
    • Market challenges
  • Market trends
    • Increased focus on generic drugs
    • Migration of manufacturing and sales facilities to APAC
    • Advancing biomedical science
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global sexual dysfunction drugs market 2016
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: Key highlights
      • Table AbbVie: Strength assessment
      • Table AbbVie: Strategy assessment
      • Table AbbVie: Opportunity assessment
    • Bayer
      • Table Bayer: Key highlights
      • Table Bayer: Strength assessment
      • Table Bayer: Strategy assessment
      • Table Bayer: Opportunity assessment
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent members
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report